Vasistera™ NIPT
Use
Vasistera™ NIPT is a noninvasive prenatal screening test that analyzes cell-free DNA from the blood of pregnant individuals to screen for common chromosomal conditions affecting the fetus, including trisomy 21, trisomy 18, trisomy 13, and sex chromosome aneuploidies. The test helps identify pregnancies with an increased risk of these genetic conditions, aiding in early intervention and informed decision-making alongside healthcare providers.
Special Instructions
Vasistera™ NIPT is a screening test and not diagnostic, meaning it cannot make a final diagnosis of chromosomal conditions. A screen positive result indicates a higher chance of a specific condition, but diagnostic follow-up with tests like chorionic villus sampling or amniocentesis is recommended for confirmation. Fetal sex reporting is optional with this test.
Limitations
Vasistera™ NIPT does not report on other chromosomal conditions such as triploidy or microdeletions like 22q11.2 deletion syndrome. The test is limited to single nucleotide polymorphism-based analysis and may not capture all genetic variations that could affect the pregnancy. It is not available for pregnancies with gestational carriers, egg donors, or dizygotic twins.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided